It's great that groups are looking at supplements, and other treatments like DCA. It's too bad that they felt the need to adjust the recipe mid trial.
Hopefully we see a better constructed, blinded study soon. One which uses objective markers. Surely with something like this which targets a specific metabolic process, we can correlate measurements of PDH activity to patient survey data.
Also, I find quotes like this dissapointing...
Something about this statement just seems rather dismissive, and suggestive that non-responders must be in some other category. I'm sure that some patients are likely in that boat, but something about the way it's written in the paper bothers me. "explaining the lack of response to nutriceutical treatment" as a statement is just cocky in the absense of a proper clinical trial with objective measure.
I think it is all good that they adjusted the recipe mid trial, I bet they just found other supplements that could help the whole experience.
Regarding the quote, I think study claims that you could divide people with ME/CFS in to two categories:
Category I. People who have ME/CFS and no other significant diseases such as multiple sclerosis, autoimmune diseases etc.
Category II. People who have ME/CFS and have other diseases
simultaneously etc - multiple sclerosis, autoimmune diseases, disorders related to endocrinology.
It would be naive to believe that DCA could help people in Category II, because Multiple sclerosis requires a whole other treatment (it causes fatigue and paralysis as well as death and only recently pharma companies in Swiss have developed biological therapy which could be the FIRST drug to actually stop MS a little bit). Autoimmune diseases require a completely different treatment and could cause fatigue, depression and other changes similar to ME/CFS. Endocrinal ilnesses such as hypogonadism mean the decrease of testosterone, once again, DCA can no be particulary helpful in such cases.
However, according to the study, a big part of
Category I patients received improvement which could be measured with objective methods. I believe that this could be huge. All they need to do i develop guidelines or some sort of tests which could be taken by people who have ME/CFS to find out if these nutriceuticals with DCA are for them.
For example, if patient A has early multiple sclerosis and hypothyroidism - DCA + Vit B, ALA etc. is probably not for him. But if Patient B is free of any other diseases which could aggreviate or result in ME/CFS symptoms - he should probably try DCA. I don't know, this just seem like a logical concept if they're planning to developing these ideas in the future.
We need as much attention from reputable people and researchers as we can get. This could be something interesting. We need more trials with bigger numbers.
Anyone know any professors that could participate in such findings ?
@msf what do you think ?
----------------------------------------
P.S. Nearly forgot. DCA doses for treating cancer are 3 times, 4 times or sometimes even 8 times larger than the doses that they've used in this pilot trial. I think the lowest threshold for DCA to be able to cause any side effects is 7,5 mg/kg (some study mentioned it). If they do develop, all the side effects are reversible by quiting DCA intake. Besides, I believe the reason they added Vitamin B1, Alpha-lipoic acid and Carnitine was to compeltely minimize any possibility of side effects (don't ask me why these supplements improve the experience of taking DCA a LOT. I've just seen it from my personal experience. You must take a lil' bit of VitB1 and Alpha lipoic acid for the best experience).
Anddd... the study somebody mentioned before. Actually, I don't think i've read that anyone died from DCA, lol. Otherwise they would have stopped all the research with the DCA + children suffering from mitochondria diseases. I believe there was one study related to brain cancer was performed over 10 years ago, but then they gave HUGE doses of DCA with no supplements to prevent side effects. It was like taking a 5 times bigger dose than here, every day on a continuous basis.